FIFumio Ishida

Fumio Ishida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fumio Ishida has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colitis-associated colorectal neoplasia in ulcerative colitis with primary sclerosing cholangitis: a nationwide study

    by Koichi Komatsu, Takahide Shinagawa, Motoi Uchino, Hiroki Ikeuchi, Koji Okabayashi, Shiro Oka, Kitaro Futami, Michio Itabashi, Kazuhiro Watanabe, Masatsune Shibutani, et al.

    Background/Aims: Ulcerative colitis (UC)-associated colorectal neoplasia (UCAN) in patients with UC and primary sclerosing cholangitis (PSC) has not been studied well in Japan. This retrospective study examined the clinicopathological features and prognosis of UCAN in patients with PSC-UC. Methods: A total of 808 patients with UCAN were enrolled from 1983 to 2020 and categorized into PSC (PSC-UCAN, n = 26) and no PSC (UCAN-alone, n = 782) groups. Clinicopathological features were compared between the 2 groups, and the 10-year overall survival (OS) and cancer-specific survival (CSS) were analyzed. Results: The PSC-UCAN group had a shorter UC duration before UCAN diagnosis (12.8 years vs. 16.9 years, P= 0.044), were younger at UCAN diagnosis (47.8 years vs. 53.3 years, P= 0.046), and developed UCAN more frequently in the right-sided colon (34.6% vs. 15.9%, P= 0.028) than the UCAN-alone group. The PSC-UCAN group showed a trend toward a lower proportion of high-grade dysplasia (19.2% vs. 30.7%) and a higher proportion of early-stage cancers (53.9% vs. 31.2%). The 10-year OS (64.6% vs. 79.3%, P=0.080) and CSS (80.8% vs. 83.9%, P=0.60) were comparable. Conclusions: Patients with PSC-UCAN showed earlier and younger development of UCAN than patients with only UCAN, with a high prevalence in the right-sided colon. Early-stage cancer was more frequently observed in the PSC-UCAN group, despite the shorter duration of UC. Patients with PSC-UC probably benefit from early initiation of surveillance colonoscopy.


  • CLINICAL AND PATHOLOGICAL FEATURES OF DEPRESSED-TYPE COLORECTAL NEOPLASM

    by Shin-Ei Kudo, Jiro Kawashima, Yuta Kouyama, Katsuro Ichimasa, Shingo Matsudaira, Hiroki Nakamura, Hideyuki Miyachi, Masashi Misawa, Noriyuki Ogata, Tomokazu Hisayuki, et al.

  • MOLECULAR AND CLINICOPATHOLOGICAL FEATURES OF DEPRESSED T2 COLORECTAL CANCER BASED ON CMS CLASSIFICATION

    by Kenichi Mochizuki, Shinei Kudo, Kazuki Kato, Koki Kudo, Yushi Ogawa, Yuta Kouyama, Yuki Takashina, Katsuro Ichimasa, Taro Tobo, Takaaki Masuda, et al.

  • Impact of non-curative endoscopic submucosal dissection on short- and long-term outcome of subsequent laparoscopic gastrectomy for pT1 gastric cancer

    by Shoji Shimada, Naruhiko Sawada, Sonoko Oae, Junichi Seki, Yojiro Takano, Kenta Nakahara, Yusuke Takehara, Shumpei Mukai, Fumio Ishida, Shin-Ei Kudo

    Background The feasibility and oncological safety of non-curative endoscopic submucosal dissection (ESD) prior to additional gastrectomy for early gastric cancer (EGC) are still unclear. The aim of this study was to evaluate the impact of non-curative ESD on short- and long-term outcomes of subsequent laparoscopic gastrectomy (LG) for pathological T1 (pT1) EGC. Methods We retrospectively investigated 422 patients who underwent LG for pT1 EGC between January 2007 and December 2017 at our center. Eighty-five of these patients underwent ESD with curative intent before surgery. Using propensity-score matching for sex, age, body mass index, American society of anesthesiologists score, history of previous abdominal surgery, tumor location, mucosal/submucosal infiltration, histology, lymph node metastasis, extent of lymph node dissection, operative method, lymphatic invasion, and venous invasion, the clinicopathologic and survival data of these patients were compared. Results The median follow-up period was 60 (range 2–168) months. Using propensity-score matching from a total of 422 patients, 75 patients were selected in the Non-ESD and the ESD cohorts each. There were no significant differences in terms of characteristics and clinicopathological findings between the two groups. Furthermore, there were no significant differences in postoperative morbidity (13.3% vs. 17.3%; P = 0.497) and mortality (1.3% vs. 0%; P = 0.316). Both the 5-year overall survival ratio (88.8% vs. 86.9%; P = 0.757) and 5-year disease-specific survival ratio (97.1% vs. 98.4%; P = 0.333) were similar in the two groups. Conclusion Short- and long-term outcomes of LG in patients with pT1 EGC are not related to preoperative ESD history. Even for non-curative resections, ESD prior to surgery is feasible in terms of oncological and surgical outcomes in pT1 EGC.


  • Open Access

    Clinical Efficacy of Endocytoscopy for Gastrointestinal Endoscopy

    by Masashi Misawa, Shin-Ei Kudo, Yuki Takashina, Yoshika Akimoto, Yasuharu Maeda, Yuichi Mori, Toyoki Kudo, Kunihiko Wakamura, Hideyuki Miyachi, Fumio Ishida, et al.

    Endocytoscopy (EC) is a contact-type optical endoscope that allows in vivo cellular observation during gastrointestinal endoscopy and is now commercially available not only in Japan but also in Asian, European Union, and Middle Eastern countries. EC helps conduct a highly accurate pathological prediction without biopsy. Initially, EC was reported to be effective for esophageal diseases. Subsequently, its efficacy for stomach and colorectal diseases has been reported. In this narrative review, we searched for clinical studies that investigated the efficacy of EC. EC seems to accurately diagnose gastrointestinal diseases without biopsy. Most of the studies aimed to clarify the relationship between endocytoscopic findings of gastrointestinal neoplasia and pathological diagnosis. Some studies have investigated non-epithelial lesions or diseases, such as inflammatory bowel disease or infectious diseases. However, there are few high-level pieces of evidence, such as randomized trials; thus, further studies are needed.


  • Artificial Intelligence System to Determine Risk of T1 Colorectal Cancer Metastasis to Lymph Node

    by Shin-Ei Kudo, Katsuro Ichimasa, Benjamin Villard, Yuichi Mori, Masashi Misawa, Shoichi Saito, Kinichi Hotta, Yutaka Saito, Takahisa Matsuda, Kazutaka Yamada, et al.


  • Open Access

    Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion

    by Yuta Sato, Shin‑Ei Kudo, Katsuro Ichimasa, Shingo Matsudaira, Yuta Kouyama, Kazuki Kato, Toshiyuki Baba, Kunihiko Wakamura, Takemasa Hayashi, Toyoki Kudo, et al.

    With recent advances in endoscopic treatment, many T1 colorectal carcinomas (CRCs) are resected endoscopically with a negative margin. However, some lesions exhibit skip lymphovascular invasion (SLVI), which is defined as the discontinuous foci of the tumor cells within the colon wall. The aim of the present study was to reveal the clinicopathological features of T1 CRCs with SLVI and validate the Japanese guidelines regarding SLVI. A total of 741 patients with T1 CRCs that were resected surgically between April 2001 and October 2016 in our hospital were divided into two groups: With SLVI and without SLVI. Clinicopathological features compared between the two groups were patient's gender, age, tumor size, location, morphology, lymphovascular invasion, tumor differentiation, tumor budding and lymph node metastasis. The incidence of T1 CRCs with SLVI was 0.9% (7/741). All cases with SLVI were found in the sigmoid colon or rectum. T1 CRCs with SLVI showed significantly higher rates of lymphovascular invasion than those without SLVI (P<0.01). In conclusion, lymphovascular invasion was a significant risk factor for SLVI in T1 CRCs, and for which surgical colectomy was necessary. The Japanese guidelines are appropriate regarding SLVI. Registered in the University Hospital Medical Network Clinical Trials Registry (UMIN000027097).


  • Open Access

    575 Narrow-Band Imaging Efficiency for Evaluation of Mucosal Healing/ Relapse of Ulcerative colitis

    by Seiko Hayashi, Shin-Ei Kudo, Noriyuki Ogata, Kazuo Ohtsuka, Kunihiko Wakamura, Yasuharu Maeda, Masashi Misawa, Yuichi Mori, Tomokazu Hisayuki, Takemasa Hayashi, et al.


  • Endocytoscopic microvasculature evaluation is a reliable new diagnostic method for colorectal lesions (with video)

    by Shin-Ei Kudo, Masashi Misawa, Yoshiki Wada, Hiroki Nakamura, Shinichi Kataoka, Yasuharu Maeda, Naoya Toyoshima, Seiko Hayashi, Makoto Kutsukawa, Hiromasa Oikawa, et al.


  • Open Access

    A case of retroperitoneal dedifferentiated liposarcoma with leiomyosarcoma and osteosarcoma components

    by Tomokatsu Omoto, Shungo Endo, Eiji Hidaka, Fumio Ishida, Jun-Ichi Tanaka, Shin-Ei Kudo, Mutsuko Omatsu

    症例は50歳,男性.左側腹部痛を主訴に前医を受診し,同部に腫瘤を指摘され紹介となった.初診時に左下腹部に圧痛を伴う可動性不良な腫瘤を触知した.血液生化学検査では炎症反応の上昇と軽度貧血を認めた.CTでは下行結腸背側に手拳大の腫瘍を認め,内部は均一で一部に石灰化を伴っていた.MRIではT1強調・T2強調像で腫瘍は不均一な高信号を示した.後腹膜腫瘍と診断し,下行結腸と一塊に腫瘍を切除した.腫瘍は10.5×7.0×7.0cm,割面は充実性で白色調の部位と黄色調の部位が混在していた.病理組織学検査では紡錘形細胞が車軸状に増殖する像を認め,悪性線維組織球腫に類似した所見であった.CDK4およびMDM2が陽性で,腫瘍内には骨肉腫と平滑筋肉種の成分も認め,骨肉腫と平滑筋肉腫への分化を示す脱分極型脂肪肉腫と診断した.